Latest-3

An-excellent-summary-about-the-potential-of-our-lead-program-oxu-001-from-drug-discovery-world. “An innovative sustained release formulation of dexamethasone currently under investigation for use in DME offers the potential for effective anti-inflammatory treatment with significantly fewer injections and a high likelihood of fewer side effects, as its levels in the vitreous and anterior segment are minimal. This will limit the frequency of IOP elevation and cataract …

Oxular in Drug Discovery World Read More »

Oxular’s Senior Medical Advisor, Prof. Marc de Smet, presented on “Managing CME via the Suprachoroidal Space” at the December 2021 IOIS Conference. His talk included an update on a hard-to-treat post-surgical macular edema patient. The Oxulumis® posterior suprachoroidal microcatheter was used under compassionate-use for the administration of Triesence. The data below shows both a gain …

2 x Triesence doses; nearly one year of response Read More »